Optimized management in patients with bladder cancer.
作者信息
Babjuk Marek
机构信息
Department of Urology, Hospital Motol and 2 Faculty of Medicine, Charles University, Prague, Czech Republic.
出版信息
Cent European J Urol. 2015;68(1):15-6. doi: 10.5173/ceju.2015.01.e93.
Abstract
摘要
相似文献
1
Optimized management in patients with bladder cancer.
Cent European J Urol. 2015;68(1):15-6. doi: 10.5173/ceju.2015.01.e93.
2
Imaging in Localized Bladder Cancer: Can Current Diagnostic Modalities Provide Accurate Local Tumor Staging?
Curr Urol Rep. 2019 Nov 28;20(12):82. doi: 10.1007/s11934-019-0948-7.
3
Supporting self-management of radiation-induced bowel and bladder dysfunction in pelvic-cancer rehabilitation: An ethnographic study.
J Clin Nurs. 2019 Jul;28(13-14):2624-2634. doi: 10.1111/jocn.14849. Epub 2019 Mar 29.
4
[Management of Ta, T1, and in situ bladder carcinoma: what is new?].
Prog Urol. 2008 May;18 Suppl 5:S94-8. doi: 10.1016/S1166-7087(08)72484-9.
5
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.
J Urol. 2011 Dec;186(6):2158-67. doi: 10.1016/j.juro.2011.07.076. Epub 2011 Oct 19.
6
Bladder cancer: overview and disease management. Part 1: non-muscle-invasive bladder cancer.
Br J Nurs. 2018 May 10;27(9):S27-S37. doi: 10.12968/bjon.2018.27.9.S27.
7
Management of muscle-invasive bladder cancer in Victoria, 1990-1995.
ANZ J Surg. 2006 Mar;76(3):113-9. doi: 10.1111/j.1445-2197.2006.03665.x.
8
Identification of a nine-gene panel as a prognostic indicator for recurrence with muscle-invasive bladder cancer.
J Surg Oncol. 2019 Jun;119(8):1145-1154. doi: 10.1002/jso.25446. Epub 2019 Mar 18.
9
The dosimetric impact of heterogeneity corrections in high-dose-rate ¹⁹²Ir brachytherapy for cervical cancer: Investigation of both conventional Point-A and volume-optimized plans.
Brachytherapy. 2012 Nov-Dec;11(6):515-20. doi: 10.1016/j.brachy.2012.01.011. Epub 2012 Mar 3.
10
Surgical management of bladder carcinoma.
Cancer Control. 2002 Jul-Aug;9(4):284-92. doi: 10.1177/107327480200900403.
引用本文的文献
1
Double-Blind, Randomized, Placebo-controlled Studies Evaluating Apaziquone (E09, Qapzola™) Intravesical Instillation Post Transurethral Resection of Bladder Tumors for the Treatment of Low-risk Non-Muscle Invasive Bladder Cancer.
Bladder Cancer. 2018 Jul 30;4(3):293-301. doi: 10.3233/BLC-180166.
2
Liquid biopsies for surveillance and monitoring treatment response of bladder cancer.
Ann Transl Med. 2016 Oct;4(19):379. doi: 10.21037/atm.2016.08.27.
3
Author'S reply.
Cent European J Urol. 2015;68(1):17. doi: 10.5173/ceju.2015.01.r95.
本文引用的文献
1
Timing of radical cystectomy in Central Europe - multicenter study on factors influencing the time from diagnosis to radical treatment of bladder cancer patients.
Cent European J Urol. 2015;68(1):9-14. doi: 10.5173/ceju.2015.01.444. Epub 2014 Dec 17.
2
Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream.
J Urol. 2015 Jan;193(1):53-7. doi: 10.1016/j.juro.2014.06.083. Epub 2014 Jul 1.
3
Care transitions between hospitals are associated with treatment delay for patients with muscle invasive bladder cancer.
J Urol. 2014 Nov;192(5):1349-54. doi: 10.1016/j.juro.2014.05.027. Epub 2014 May 14.
4
Longer wait times increase overall mortality in patients with bladder cancer.
J Urol. 2009 Oct;182(4):1318-24. doi: 10.1016/j.juro.2009.06.041. Epub 2009 Aug 14.
5
A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome.
BJU Int. 2007 Nov;100(5):1015-20. doi: 10.1111/j.1464-410X.2007.07132.x. Epub 2007 Sep 3.
6
Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.
J Urol. 2007 Apr;177(4):1283-6; discussion 1286. doi: 10.1016/j.juro.2006.11.090.
Zotero 插件